flow trial semaglutide kidney outcomes 2024 nejm hazard ratio Original Article: Effects of on Chronic Disease in Patients with Type 2 Diabetes (FLOW) https://t.co/Q9DAA6mPte @ERAkidney ADA 24: FLOW Trial: Kidney

The patient ultimately developed bradycardia and pulseless electrical activity

The best follow-ups failed to support it any risk elevation, and other work has suggested that NAION and problems like it might be specific to certain identifiable subgroups

Understanding the specific dose you are using helps calibrate expectations for both benefits and side effects

In peptide therapy, specific peptides are used to support metabolic health, fat burning, and recovery, often with fewer side effects than pharmaceuticals

WASHINGTON The Trump administrations grand bargain with drugmakers on GLP-1s was based on a simple premise: lower prices in exchange for higher sales volume